New vaccine takes on deadly brain tumors in early trial
NCT ID NCT03914768
First seen Jun 16, 2026 · Last updated Jun 16, 2026
Summary
This study tests a custom-made vaccine for people with two serious brain cancers: glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The vaccine is made from the patient's own immune cells and designed to teach the body to attack the tumor. The main goals are to check if the vaccine is safe and to see if it can help patients live longer. Up to 10 participants aged 6 months to 80 years will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE INTRINSIC PONTINE GLIOMA OR GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Neurosurgery, Shenzhen Hospital, Southern Medical University
Shenzhen, Guangdong, 518100, China
-
Shenzhen Children's Hospital
Shenzhen, Guangdong, 518038, China
-
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, 518000, China
Conditions
Explore the condition pages connected to this study.